DDR genes analysis and PARP-inhibitors therapy as tailored management in metastatic prostate cancer: achieved answers, open questions and future perspectives

Minerva Urol Nephrol. 2022 Dec;74(6):649-652. doi: 10.23736/S2724-6051.22.05185-0.

Authors

Alessandro Sciarra^{1

2}, Cristian Fiori^{3

4}, Francesco Del Giudice^{3

4}, Giovanni DI Pierro^{3

4}, Giulio Bevilacqua^{3

4}, Alessandro Gentilucci^{3

4}, Susanna Cattarino^{3

4}, Gianna Mariotti^{3

4}, Stefano Salciccia^{3

4}

Affiliations

¹ Mother-Child and Urologic Sciences Department, Sapienza University, Rome, Italy - alessandro.sciarra@uniroma1.it.
² Department of Urology, University of Turin, Orbassano, Turin, Italy - alessandro.sciarra@uniroma1.it.
³ Mother-Child and Urologic Sciences Department, Sapienza University, Rome, Italy.
⁴ Department of Urology, University of Turin, Orbassano, Turin, Italy.

PMID: 36629806
DOI: 10.23736/S2724-6051.22.05185-0

No abstract available

MeSH terms

DNA Damage
Humans
Male
Poly(ADP-ribose) Polymerase Inhibitors* / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors* / therapeutic use
Prostatic Neoplasms* / drug therapy
Prostatic Neoplasms* / genetics
Prostatic Neoplasms* / pathology

Substances

Poly(ADP-ribose) Polymerase Inhibitors